Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)

Back

HFA Premium Access

Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)

Session: Cardiac amyloidosis from epidemiology to treatment

Topic: Autoimmune/Chronic Inflammatory Disorders and Heart Disease

Speaker: Doctor J. Inamo (Fort de France, MQ)

Event: Heart Failure 2023

Congress Presentation

About the speaker

Doctor Jocelyn Inamo

University Hospital of Fort de France, Fort de France (Martinique)

0 follower

4 more presentations in this session

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study

Speaker: Professor N. Piriou (Nantes, FR)

Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals

Speaker: Doctor S. Selvaraj (Durham, US)

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Speaker: Doctor A. Ioannou (Greater London, GB)

Effect of patisiran treatment in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy: post-hoc analysis of the APOLLO-B study

Speaker: Professor F. Gustafsson (Copenhagen, DK)

Access the full session

Cardiac amyloidosis from epidemiology to treatment

Speakers: Doctor J. Inamo, Professor N. Piriou, Doctor S. Selvaraj, Doctor A. Ioannou, Professor F. Gustafsson

Access

Video

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)

About the speaker

Doctor Jocelyn Inamo

4 more presentations in this session

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study

Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals

Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping

Effect of patisiran treatment in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy: post-hoc analysis of the APOLLO-B study

Access the full session

Cardiac amyloidosis from epidemiology to treatment

About the event

Heart Failure 2023

ESC 365 is supported by